A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer

This multicenter, randomized, double-blind study will estimate the efficacy, safety and
tolerability of ipatasertib combined with paclitaxel compared with placebo combined with
paclitaxel in participants with inoperable locally advanced or metastatic triple-negative
breast cancer (mTNBC), as measured by progression-free survival (PFS) in all participants and
in participants with phosphatase and tensin homolog (PTEN)-low tumors.